Introduction
Tamoxifen (TAM) is an effective endocrine therapy in $60% of all estrogen receptor alpha (ERa) positive/progesterone receptor positive breast cancers. The inhibitory effect of TAM is observed almost exclusively in breast tumors that are ERa positive because estrogen is the major growth stimulator for these types of tumors. However after prolonged antiestrogen hormonal therapy, breast cancer often progresses from an estrogen-sensitive state to an estrogen-insensitive state (1) . Although the development of TAM resistance may be a consequence of ERa loss, TAM resistance most often occurs despite expression of ERa (2) (3) (4) . In these cases, constitutive overexpression of autocrine growth factor or growth factor receptor by tumor cells has been proposed as one possible mechanism of TAM resistance (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Increased autocrine or paracrine growth factor signaling networks bypass the classical ER-mediated signaling pathway in human breast cancer cells and result in failure of antiestrogen therapy. For example, preclinical and clinical studies have reported a decreased efficacy of TAM in tumors overexpressing c-ErbB2 (6, (14) (15) (16) and PC cell-derived growth factor (PCDGF/GP88) (17) . Activation of the ras/mitogen-activated protein kinase (MAPK/ERK1/2) pathway known to lie downstream of growth factor receptor signaling can cause ligand-independent activation of ERa (18) (19) (20) (21) . Protein kinase C (PKC) isozymes are known to modulate MAPK/ERK1/2 signaling pathways (22, 23) ; PKC-mediated activation of MAPK/ERK1/2 can directly phosphorylate ER Ser-118 (18, 21) , a site normally phosphorylated in response to estrogen itself by a MAPK-independent mechanism (24) . These studies provide additional mechanistic explanations for how signaling by growth factor receptors can result in hormone independence/TAM resistance.
PKC is a family of serine/threonine protein kinases, which mediate a multitude of effects regulating cellular proliferation and differentiation (25) . The family consists of 12 isozymes, a, bI, bII, g, d, e, x, q, h, i, m and n, which can be classified into three subgroups-conventional, novel and atypical (26) . Conventional isozymes are activated by diacylglycerol (DAG), phorbol esters and calcium, and include isozymes a, bI, bII and g, novel isozymes d, e, h, and q are activated by DAG/phorbol esters but are calcium-independent and atypical isozymes including z and i/l are unresponsive to DAG/phorbol esters and calcium. In addition to differences in their cofactor requirements, these isozymes also differ in tissue expression, sub-cellular localization,, and substrate specificity. It is well documented that ER and PKC activity are inversely related in breast cancer cell lines (27) and PKC is elevated in malignant versus normal breast tissue (27) (28) (29) .
We have shown previously that the ERa-negative/ hormone-independent human breast cancer cell line T47D:C42 has elevated PKCa protein expression compared with the ERa-positive/hormone-dependent T47D:A18 clone (30) . Stable overexpression of PKCa in T47D:A18 cells produces clones that are able to grow in the absence of hormonal stimulation and, thus, exhibit autonomous growth in vitro (30) . Tumors derived from T47D:A18/PKCa clones also display autonomous growth, are TAM-resistant and growth inhibited by 17b-estradiol (E2) in vivo (31) . Interestingly, stable overexpression of PKCa also results in increased endogenous expression of PKC isozymes b and d (30) . It was reported previously that stable transfection of PKCa results in upregulation of PKCb in MCF-7 cells (32, 33) and PKCd in murine lymphoma and promylelocytic cells (34) . To study the contribution of PKCs a, b and d to the growth phenotype of T47D:A18/PKCa cells and tumors, two approaches were employed: (i) PKCa expression in the T47D:A18/PKCa20 clone was selectively knocked down by using short hairpin RNA (shRNA) technology and (ii) Stable PKCs b and d clones were established in T47D:A18 and the hormone-responsive phenotypes of these clones were examined.
Materials and methods
Cell lines and culture conditions T47D:A18 is a hormone-dependent human breast cancer cell clone that was described previously (35) . T47D:A18/neo and T47D:A18/PKCa20 clones have been described previously (30) . T47D:A18, T47D:A18/neo and T47D:A18/PKCa20 clones were maintained in RPMI-1640 phenol-red medium supplemented with 10% fetal bovine serum (FBS). T47D:A18/neo and T47D:A18/PKCa20 clones were also supplemented with G418 (500 mg/ml). Prior to cell proliferation assays, all cell lines were maintained in phenol red-free RPMI-1640 supplemented with 10% 3· dextran-coated charcoal (DCC)-treated FBS (estrogen-depleted media) for 3 days. Prior to transient transfection experiments for northern blots, all cell lines were grown in complete medium containing 10% FBS.
RNA isolation and northern blot
PKCs a, b and d cDNAs were cloned in order to synthesize the antisense riboprobes. Total RNA was isolated from the T47D:A18 clones using the Triazol reagent (Invitrogen, Carlsbad, CA). PKCs b and d cDNA fragments were obtained from total RNA by RT-PCR by using the following primers sets: PKCb-forward (5 0 -CAGAAGGCCAGTGTTGATGGCTGG-3 0 ) and PKCb-reverse (5 0 -TCTGTTGCCATTGTTGTCAAATTT-3 0 ); PKCd-forward (5 0 -GCCTTCAACTCCTATGAGCTGGGC-3 0 ) and PKCd-reverse (5 0 -GTCCTCCAGGAAATACTGAACAGA-3 0 ). The 1.3 kb EcoRI fragment of the PKCa gene was obtained by digestion of the PKCa clone (obtained form ATCC, Rockville, MD) with EcoRI. The resulting DNA fragments were cloned into the pGEM-T vector (Promega, Madison, WI) to obtain the PKCs a, b and d recombinant plasmids. After sequencing and determination of the insert orientation, the recombinant plasmids were used to synthesize DIG-labeled antisense riboprobes by the RNA labeling kit according the manufacturer's instructions (Roche Diagnostics Corporation, Indianapolis, IN). For gene expression studies, total RNA (10-20 mg) was isolated from T47D cell lines and electrophoresed on 1% agarose gels containing 2.2 M formaldehyde, transblotted onto nylon membranes using the TransBlot system (BioRad Laboratories, Hercules, CA) and fixed to the membrane by UV cross-linking. Hybridization was carried out at 68 C for 16 h in 50% formamide hybridization solution containing 20 ng/ml RNA probe. Following hybridization, the membrane was washed twice at room temperature with 2· SSC buffer (30 mM sodium citrate (pH 7.0) and 300 mM NaCl) containing 0.1% SDS and twice at 68 C with 0.5· SSC buffer containing 0.1% SDS. For detection, anti-DIG-AP antibody was used in conjunction with CDP-star chemiluminescent reagent. Bands were quantified by Scion image software (Scioncorp.com).
Construction of shRNA plasmids
The pSUPER vector, which directs the synthesis of shRNAs, was a gift from Dr Yin Mo (Southern Illinois University) (36) . The shRNA sequences of human PKCa corresponded to the coding regions 492-510 relative to the first nucleotide of the start codon (37) . The sense oligonucleotide sequence containing the human PKCa shRNA pair (underlined sequence) is as follows: 5 0 -GATCCCC(AAAGGCTGAGGTTGCTGAT)TTCAAGAGA(ATCAGCAAC-CTCAGCCTTT)TTTTTGGAAA-3 0 , and the antisense oligonucleotide sequences containing the human PKCashRNA sequence is AGCTTTTC-CAAAAA(AAAGGCTGAGGTTGCTGAT)TCTCTTGAA(ATCAGCAACC-TCAGCCTTT)GGG-3 0 . The non-silencing shRNA control sequences were designed according to the non-silencing shRNA (NS-shRNA) sequence available at www.qiagen.com. The sense oligonucleotide sequence containing NS-shRNA pair (underlined sequence) is GATCCCC(TTCTCCGAACGTGT-CACGT)TTCAAGAGA(ACGTGACACGTTCGGAGAA) TTTTTGGAAA, and antisense oligonucleotide containing NS-shRNA pair (underlined sequence) is 5 0 -AGCTTTTCCAAAAA(TTCTCCGAACGTGTCACGT)TCTCTTGAA-(ACGTGACACGTTCGGAGAA)GGG-3 0 .
To generate shRNA duplexes, 0.2 mM sense and antisense oligonucleotides were annealed by incubating the mixed oligonucleotides in the PCR thermocycler using the following profile: 95 C for 30 min, 80 C for 30 min, 70 C for 30 min and room temperature for another 30 min. Double stranded oligonucleotides were subsequently cloned into the pSUPER plasmid in the frame of the BglII and HindIII sites. The inserts were screened by restriction enzyme digestion with EcoRI and HindIII and confirmed by sequencing with M13 forward and reverse primers (DNA Sequencing Facility, University of Chicago).
Partial PKC purification and western blot A PKC-enriched fraction was purified from at least 4 · 10 8 cells by DEAEcellulose anion exchange column chromatography as previously described (38) . Protein concentration was measured using the BCA assay (Pierce, Rockford, IL). An 8% SDS-polyacrylamide gel was loaded with equal amounts of protein (50-100 mg/lane) and biotin-labeled molecular weight standards to approximate protein size. Following electrophoresis, protein was transferred to Hybond-ECL nitrocellulose membranes (Amersham Life Sciences, Buchinghamshire, England) by semi-dry electroblot transfer. PKC isozyme polyclonal antibodies a, b and d (Santa Cruz Biotechnology, Santa Cruz, CA) were diluted 1:500 in TBS-T [20 mM Tris (pH 7.6), 137 mM NaCl and 0.1% Tween-20] containing 5% dry milk. The Supersignal western blotting detection system (Pierce, Rockford, IL) was used to visualize immunoreactive bands. Equal loading of total protein was assessed by stripping and reprobing the membrane with a b-actin monoclonal antibody (Sigma Chemical. St Louis. MO).
Generation of T47D:A18/PKCb, T47D:A18/PKCd and T47D:A18/PKCa/ shRNA stable transfectants The pSPKCs bII and d expression plasmids were generously provided by Eli Lilly (39) . pSUPER-PKCashRNA and pSUPER-NS-shRNA plasmids were constructed as described in the previous section. To generate the stable PKCashRNA clones in T47D:A18/PKCa20 cells, the pSUPER-PKCa-shRNA construct was co-transfected with pcDNA3.1/LacZ plasmid (Invitrogen, Carlsbad, CA) into T47D:A18/PKCa20 cells by electroporation (250 V, 950 mF). pSUPER or pSUPER-NS-shRNA was also transfected by electroporation into T47D:A18/PKCa20 cells as vector or non-silencing shRNA control. The transfection mixture was added to 10 ml RPMI-1640 media (phenol red +) containing 10% FBS and seeded into 100 mm tissue culture dishes. Following incubation for 2 days, the medium was replaced with medium containing both G418 (500 mg/ml) and hygromycin B (100 mg/ml). Individual colonies were picked following 3 weeks of selection and screened for PKCs a, b and d expression by western blot analysis. To generate PKCb or d stable clones in T47D:A18 cells, pSPKCs bII, d or pSVHNX-neo (control) (39) were transfected into T47D:A18 cells by electroporation. Clones designated T47D:A18/neo, T47D:A18/b13, T47D:A18/b16, T47D:A18/d14, T47D:A18/ PKCa20/shRNA#19 and /PKCashRNA#20 were chosen for further characterization.
Proliferation assay
The cell clones T47D:A18/neo, T47D:A18/PKCa20, T47D:A18/PKCb13 or 16, T47D:A18/d14 and T47D:A18/PKCa20/shRNA#19 or /shRNA#20 were seeded at 3 · 10 4 cells/ml estrogen-depleted media into T25 tissue culture flasks. The following day (day 1) medium containing either ethanol (control), E2 (10 À9 M) or 4-hydroxytamoxifen (4-OHT) (10 À7 M) was added. All compounds were dissolved in 100% ethanol and added to the medium at a 1:1000 dilution. Cells were counted on Day 2-10.
Establishment of T47D:A18/PKCb, PKCd, T47D:A18/PKCa/shRNA#19 and/ shRNA#20 tumors in athymic mice T47D:A18/neo, T47D:A18/PKCb13, T47D:A18/PKCd14, T47D:A18/ PKCa20 and T47D:A18/PKCa20/PKCashRNA#19 or /shRNA#20 cells were injected s.c. (1 · 10 7 cells/site) into the axillary mammary fat pads of ovariectomized 5-6-week-old BALB/c athymic mice (Harlan Sprague Dawley, Madison, WI). Mice were divided into three treatment groups consisting of 10 mice/group: control (no treatment); E2 (E2 capsule); or TAM. E2 was administered via silastic capsules (1.0 cm) implanted s.c. between the scapules and the capsules were replaced every 8 weeks. TAM was administered p.o. at a dose of 1.5 mg/animal daily for 5 days as described previously (31) . Tumor cross-sectional area was determined weekly by Vernier calipers and calculated using the formula: (length/2) · (width/2) · p . Mean tumor area was plotted against time in weeks to monitor tumor growth. The mice were killed by CO 2 inhalation and cervical dislocation. Tumors were excised and snap frozen in liquid nitrogen and stored at À80
C.
Overexpression of PKCa in breast cancer
Statistical analysis When comparing with one group, data were analyzed using unpaired t-test. When comparing groups, data were analyzed using One-way Analysis of Variance (ANOVA) followed by the Dunnett multiple comparison test. All statistics were performed using GraphPad InStat version 3.00 for Windows 95 (GraphPad Software, San Diego California USA). Significant differences were indicated when P < 0.05.
Results
shRNA-mediated degradation of the PKCa mRNA in T47D:A18/PKCa20 cells To determine whether the pSUPER-PKCa-shRNA construct could produce shRNA specific to PKCa mRNA degradation, T47D:A18/PKCa20 cells were transiently transfected with pSUPER, pSUPER-NS-shRNA and pSUPER-PKCa-shRNA constructs. The cells were harvested 48 or 60 h posttransfection, and PKCs a, b and d mRNA levels were measured by northern blot analysis. More than 80% of the PKCa mRNA was degraded when cells were transfected with the pSUPER-PKCa-shRNA construct (10 mg) for 48 h ( Figure 1A ). PKCa mRNA was not affected by either pSUPER vector or non-silencing RNA construct (pSUPER-NS-shRNA) at the same dose for the same period of time. Interestingly, PKCb mRNA expression was reduced to 61% when the cells were transfected with 10 mg of the pSUPER-PKCa-shRNA construct compared with the pSUPER-NS-shRNA control vector at 48 h post-transfection and this reduction was statistically significant ( Figure 1C) . However, no effect on PKCb mRNA expression was observed at 60 h post-transfection suggesting the knockdown was modest and transient. Expression of PKCd mRNA was not affected. ( Figure 1A ). These results suggest that the PKCa-shRNA also targeted PKCb mRNA destruction, even though the target sequence was in a region not homologous to PKCb. Alternatively, PKCb mRNA may be transcriptionally downregulated secondary to the decrease in PKCa expression. There is evidence in the literature for cross-regulation between PKC isozymes (32-34).
Generation T47D:A18/PKCa20/shRNA stable transfectants To verify that reduction of the PKCa mRNA corresponded to a decrease in PKCa protein, pSUPER-PKCa-shRNA and pcDNA3.1/LacZ were stably co-transfected into T47D:A18/ PKCa20 cells, and individual clones were selected in the medium containing G418 (500 mg/ml) and hygromycin (100 mg/ml) for 2 months. Several stable clones were screened by western blot analysis for PKC isozyme expression. T47D:A18/PKCa20/shRNA stable clone nos 19 and 20 exhibited a 50% reduction of PKCa protein expression compared with parental T47D:A18/PKCa20 cells (Figure 2 ). Consistent with the observed effect of PKCa-shRNA on PKCb mRNA expression, endogenous PKCb protein was also decreased in these stable clones when using a PKCb1 antibody from Santa Cruz Biotechnology (Figure 2 Ã P < 0.05 using ANOVA. ÃÃ P < 0.05 using the Dunnett multiple comparisons test post-test.
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autonomous growth phenotype of the T47D:A18/PKCa20/ shRNA stable clones were assessed by proliferation assays. As expected, all clones grew in the presence of E2 ( Figure 3A) . However, in the absence of E2, although both shRNA clones grow at a slower rate, neither of the clones exhibited reversal of autonomous growth ( Figure 3B ). These results suggest that 50% reduction of PKCs a and b protein expression is not sufficient to reverse the autonomous growth of T47D:A18/PKCa cells in vitro.
T47D:A18/PKCa20/shRNA stable clones exhibit partial reversal of the TAM-resistant and E2 inhibitory phenotypes in vivo We have reported that tumors derived from the T47D:A18/ PKCa20 clone grow in the absence of E2 (autonomous growth), in the presence of TAM, and these tumors are growth inhibited by E2 (31) . To determine whether downregulation of PKCs a and b can reverse this phenotype in vivo, we injected T47D:A18/PKCa20/shRNA stable clones into the mammary fat pads of ovariectomized athymic mice. The mice were divided into three treatment groups; no treatment (controls), E2 (1.0-cm capsule) or TAM (1.5 mg/day, p.o. five times per week). The T47D:A18/PKCa/shRNA#19 clone exhibited partial reversal of the TAM-resistant and E2 inhibitory phenotype in vivo ( Figure 4A ). However, the T47D:A18/ PKCa/shRNA#20 clone remained TAM-resistant, hormoneindependent and growth inhibited by E2 ( Figure 4B ). The partial phenotypic change exhibited by the T47D:A18/ PKCa/shRNA#19 tumor correlated with 50% reduction of PKCa expression, whereas no reduction of PKCa expression is evident in the T47D:A18/PKCa/shRNA# 20 tumors ( Figure 4C and D) . Therefore, reduction in PKCa protein correlates with the partial reversal of phenotype observed with the T47D:A18/PKCa/shRNA#19 tumor. Interestingly, downregulation of PKCb was not observed in either of the PKCa-shRNA tumors compared with parental T47D:A18/ PKCa20 tumors ( Figure 4C and D) . These results suggest that 50% reduction of PKCa alone is sufficient to partially reverse the TAM-resistant and E2-inhibitory phenotype of T47D:A18/PKCa tumors. However, the partial knockdown To determine the contribution of PKCs b and d to the autonomous growth phenotype, hormone responsiveness was determined in T47D:A18/PKCb and /PKCd stable clones by cell proliferation assay. T47D:A18/neo, T47D:A18/PKCb and /PKCd clones were unable to grow in estrogen-depleted medium or in the presence of 4-hydroxytamoxifen (4-OHT) ( Figure 6A, C and D) . However, these clones grow in response to E2 treatment, thereby exhibiting a hormone-dependent growth phenotype. Only T47D:A18/PKCa20 clones were able to grow in estrogen-depleted medium and in medium containing 4-OHT and E2 ( Figure 6B ), exhibiting autonomous growth and partial TAM-resistance.
PKCs b or d stable clones exhibit a hormone-dependent phenotype in vivo
We have shown that overexpression of PKCb and/or d in T47D:A18 results in a hormone-dependent phenotype in cell culture. To determine whether this phenotype is maintained in vivo, we injected T47D:A18/PKCb13 or T47D:A18/PKCd14 cells into the mammary fat pads of ovariectomized athymic mice. Seven weeks after the injection of T47D:A18/neo cells, E2 significantly stimulated tumor growth compared with the control and TAM groups ( Figure 7A ), which is consistent with previous findings (31) . Eight weeks post-injection of T47D:A18/PKCb or /PKCd cells, tumor growth was observed only in the E2 group ( Figure 7B, C) . No tumor was detected in any of the mice in the Control or TAM groups, exhibiting similar growth characteristics as the parental T47D:A18 
Discussion
TAM resistance is a considerable obstacle in the management of breast cancer. Therefore, identification of key molecules involved in TAM-resistance will be the critical first step in the development of a logical targeted therapy (31) . We recently reported that elevated PKCa expression may be predictive of TAM treatment failure (40) . Our in vivo T47D:A18/ PKCa20 tumor model exhibits autonomous, TAM-resistant and E2-inhibitory growth characteristics (31) . However, in addition to PKCa, the T47D:A18/PKCa20 clone also exhibits increased endogenous expression of PKCs b and d (30) . To explore the contribution of PKCs a, b and d to the autonomous, TAM-resistant and E2-inhibitory growth phenotype, two approaches were taken; (i) PKCa was specifically downregulated in T47D:A18/PKCa20 cells by shRNA and (ii) T47D:A18 cells were stably transfected with either PKCb or d.
RNA silencing or interference (RNAi) is a process of posttranscriptional gene silencing initiated by double-stranded (dsRNA) molecules (41) . To determine whether downregulation of PKCa alone is sufficient to reverse the growth characteristics of T47D:A18/PKCa20 cells, shRNA technology was utilized. The pSUPER-PKCa-shRNA construct produced shRNA that knocked down PKCa mRNA and protein by 80 and 50%, respectively. In cell culture, we found that PKCa-shRNA also resulted in downregulation of PKC b mRNA and protein, whereas PKCd expression was unaffected. One possible explanation for this observation is the cross-regulation of PKC isozymes known to exist in cell systems as reported previously (34) . Reduction in PKCs a and b in cell culture is not sufficient to reverse autonomous growth in vitro (Figure 3) . Interestingly, although tumors were derived from both T47D:A18/ PKCa/shRNA constructs, only the T47D:A18/PKCa/shRNA#19 clone produced tumors exhibiting 50% knockdown of PKCa protein. Furthermore, these tumors do not display concomitant PKCb downregulation ( Figure 4C ). It is only these T47D:A18/PKCa/shRNA#19 tumors that also exhibit reversal of TAM-resistance and E2-inhibition ( Figure 4A ). The growth characteristics of Overexpression of PKCa in breast cancer the T47D:A18/PKCa/shRNA#20 tumors are not altered and this correlates with no reduction in PKCa or b protein ( Figure 4B-D) . Despite the reduction of PKCa protein observed in the T47D:A18/PKCa/shRNA#19 tumors, these tumors retain the autonomous growth characteristic and are able to grow in the absence of hormonal stimulation. This finding is consistent both in vitro and in vivo ( Figures 3B  and 4B ) and suggests that perhaps 50-80% PKCa downregulation is not sufficient to reverse this phenotype. Since the T47D:A18 cells have virtually undetectable levels of PKCa protein as determined by western blot analysis [ Figure 5 ; (30)], it is not surprising that a 50% reduction of PKCa would not restore the parental phenotype entirely. The apparent lack of PKCa knockdown in the T47D:A18/PKCa/shRNA#20 tumors may be due to loss of the PKCa-shRNA construct during development of the tumors. These results suggest that PKCa is required to mediate the TAM-resistant and E2-inhibitory phenotype in T47D:A18 cells. The partial reversal of the TAM-resistant and E2-inhibitory phenotype may be due to the incomplete knockdown of PKCa and/or potential synergistic effects with PKCb and/or d. This possibility is supported by studies showing that both PKCs a and d are highly expressed in three out of four antiestrogen resistant MCF-7 cell lines (42) . However, in our cell and tumor models, PKCa appears to play a dominant role in the acquisition of TAM-resistance, autonomous growth and E2 inhibitory growth characteristics. Interestingly, the PKCa gene, PRKCA, maps to chromosome 17q22-q23.2 according to the genome-draft assignment, and was fine-mapped by flourescence in situ hybridization (FISH) analysis to be located at 17q24 (43) . Several genes involved in the pathogenesis of malignant breast cancer are found on chromosome 17 including p53, Her-2/neu/ ERBB2, BRCA1 and nm23 (44) . It is interesting to speculate whether upregulation of PKCa occurs along with alterations of these well-known breast-cancer-associated genes in this highly mutation-susceptible locus in breast cancer. Using dominant negative mutants of PKCa in MCF-7 cells, PKCa-specific downstream signaling targets were identified (45) . In these experiments, the dominant negative PKCa construct downregulated the anti-apoptotic bcl-2 protein and sensitized cells to apoptosis in response to TAM. In addition, the cyclindependent kinase inhibitor, p21 cip1 , was also downregulated. The authors conclude that PKCa overexpression leads to upregulation of both bcl-2 and p21 cip1 , thus, protecting cells from apoptosis. These effects were not observed using dominant negative PKCe or z constructs. Other PKCa downstream signaling molecules implicated in TAM-resistance include AP-1 (46-48), PI3K/Akt (49, 50) , MAPK (51, 52) and NFkB (53) (54) (55) . We demonstrated that the T47D:A18/PKCa20 cells exhibit elevated basal AP-1 activity compared with the T47D:18/neo vector control cells (30) . In addition, elevated phospho-Akt protein levels were observed in TAM-treated T47D:A18/PKCa20 tumors compared with tumors treated with E2 (manuscript submitted). However no difference in expression of total and phosphorylated ERK1/2 (phospho-p44/42) nor NFkB signaling components (phosphoNFkBp65, Ser32phospho-IkB) was observed in T47D:A18/ PKCa20 and T47D:A18/neo cells (unpublished observations). We continue to explore and attempt to connect the molecular signaling pathways initiated by PKCa leading to TAMresistant, E2-inhibitory, autonomous growth.
In summary, we find that PKCb and/or d overexpression is not sufficient to impart autonomous, TAM-resistant and E2-inhibited growth to T47D:A18 cells and tumors. However, partial suppression of PKCa results in partial reversal of TAMresistance and E2-growth inhibition. This finding may have important therapeutic implications. TAM has been used to treat all stages of ERa-positive breast cancer (56); however, highdose estrogen also causes tumor regression in post-menopausal women with ERa-positive breast cancer (57, 58) . We reported previously that overexpression of PKCa may predict TAM treatment failure (40) and, therefore, may be a prognostic indicator for TAM-resistance. Furthermore, the E2-induced tumor regression observed in our pre-clinical xenograft model suggests that perhaps selection of patients with PKCaoverexpressing tumors may greatly improve the efficacy of high-dose estrogen treatment, a therapeutic approach likely to be superior to TAM in this situation. Perhaps treatment of breast cancer with the PKCa antisense oligonucleotide Affinitak (LY900003/ISIS 3521) (59) can be improved by identification of patients who exhibit PKCa overexpression. Finally, the recent favor of aromatase inhibitor therapy over TAM (60-62) is another potential concern for patients harboring tumors that overexpress PKCa. Eliminating all estrogen may in fact cause tumor growth. We are currently in the process of developing a pre-clinical model to address the utility of aromatase inhibitors in this setting and determining the signaling pathway mediated by PKCa leading to E2-induced tumor regression. Elucidation of the mechanism is likely to lead to additional therapeutic targets for the treatment of breast cancer.
